Loading
Latest filing published 02 Jul 2021 for Regenerx Biopharmaceuticals INC.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
This profile gathers the share dealings of Paolo Cavazza across 4 companies, led by Sciclone Pharmaceuticals Inc, Regenerx Biopharmaceuticals Inc and Questcor Pharmaceuticals Inc. Between 31 January 2006 and 30 June 2021, the trades on record add up to 76 filings.
In open-market terms, that means 56 purchases worth €24.1M on one side and 7 sales worth €40.6M on the other. No amount is published for 7 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 10 share grants. 2021 to date brings 1 purchase and no sales.
Half of the purchases are above €57k and half below.
On 2 July 2021 came the latest disclosure, an open-market purchase for €253k in Regenerx Biopharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration